



KM Biologics Co., Ltd.



Meiji Seika Pharma Co., Ltd.

NEWS RELEASE

March 4, 2025

Meiji Seika Pharma Invests in Osivax SAS

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo; President: Daikichiro Kobayashi) and KM Biologics Co., Ltd. (Head Office: Kumamoto, Japan; President and Representative Director: Toshiaki Nagasato) are pleased to announce that Meiji Seika Pharma has invested in Osivax SAS (Head Office: Lyon, France, Chief Executive Officer and Co-founder: Alexandre Le Vert, Osivax) on 27th December, 2024.

Osivax is currently developing OVX836, a broad-spectrum universal influenza vaccine candidate designed to provide protection against a wide range of influenza viruses, including highly mutating seasonal and pandemic strains. The vaccine candidate is based on Osivax's proprietary self-assembling nanoparticle technology and aims to produce a vaccine that is effective against a wide range of influenza viruses. The lead program, OVX836, is currently in Phase II clinical trials and has been evaluated by more than 1,200 participants across multiple studies.

As part of its broader collaboration with Osivax, KM Biologics has entered into an option agreement to exercise an exclusive license to develop, manufacture and sell the Osivax's vaccine candidates in Japan.

This investment will accelerate Osivax's continued preclinical and clinical development efforts and strengthen the cooperative relationship between Meiji Seika Pharma and KM Biologics and Osivax.

By responding to the diversifying needs of the vaccine market, Meiji Seika Pharma and KM Biologics will contribute to the improvement of public health by further enhancing vaccination rates and reducing disease burden.

About Osivax

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM™, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum “universal” influenza vaccine candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 volunteers tested and encouraging efficacy proof of concept data. Osivax’s ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.

For further information: <https://osivax.com/>